drugset
drugset / Trial / NCT06237400

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

NCT06237400 ↗

Phase 1/2 Unknown 110 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedSequentialOpen-labelTreatment

Summary

Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.

Timeline

Start
2022-05-26
Primary completion
2025-05
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG19018 Unknown 50 mg Oral
Subject ZG19018 Unknown 150 mg Oral

Indications

No indication recorded.